Liquid Biopsy Market By Products PowerPoint PPT Presentations

Increase in incidences and prevalence of various cancer types, rise in demand for safe and non-invasive procedures, and advantages of liquid biopsy launches and technology drive the growth of the global liquid biopsy market. However, lack of awareness in developing and underdeveloped regions hinder the market growth. On the other hand, use of liquid biopsy for treatment of rare cancer and untapped potential of emerging markets present new opportunities in the coming years.

The Global Liquid Biopsy Market is expected to register 28.0% CAGR and is projected to reach USD 17,372.28 million by 2022.

Global liquid biopsy for cancer diagnostics market size is expected to reach $16.42 Bn by 2028 at a rate of 15.7%, segmented as by type, product, services

The Global Liquid Biopsy Market is expected to register 28.0% CAGR and is projected to reach USD 17,372.28 million by 2022.

Liquid Biopsy Market Forecast to 2027 – COVID-19 Impact and Global Analysis – by Product & Services (Equipment, Reagents & Kits, and Services), Sample (Blood Based, Urine Based, and Other Samples), Circulating Biomarker [Circulating Tumor Cells (CTC), Exosomes, and Free Nucleic Acid], Application [Noninvasive Prenatal Testing (NIPT), Oncology, Transplant Diagnostics, and Other Applications], and End User (Academic & Research Institutes, Hospitals, Reference Laboratories, and Other End Users)

Liquid biopsy reduces the apprehension of patients regarding pain and provides a safe and effective method of diagnosis. As a result, there has been increasing demand for a non-invasive alternative, such as liquid biopsy, over tissue biopsy that involves the painful extraction of diseased tissue, which is fueling the market growth. Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: Visit the following link: https://www.imarcgroup.com/liquid-biopsy-market E-mail: sales@imarcgroup.com Contact: +91-120-415-5099

According to the latest research report by IMARC Group, The global liquid biopsy market size reached US$ 1.8 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.3 Billion by 2028, exhibiting a growth rate (CAGR) of 15.3% during 2023-2028. More Info:- https://www.imarcgroup.com/liquid-biopsy-market

Global liquid biopsy market size is expected at $20.39 Bn by 2027 at a growth rate of 32.2% Growth Analysis by The Business Research Company.

The liquid biopsy market size is projected to reach US$ 8,123.85 million by 2027 from US$ 3,861.49 million in 2019. The liquid biopsy market CAGR is estimated to grow at 9.9% from 2020 to 2027.

The major players in the liquid biopsy market are QIAGEN N.V., Roche Diagnostics, Bio-Rad Laboratories Inc., Myriad Genetics, Inc...@ @ https://bit.ly/3qTxZfD

iGATE Research has released a research report on “Liquid Biopsy Market (by Circulating Biomarker, Product, Application, End User, Clinical Application, Cancer Types, Sample Type, Regional & Country Wise Analysis), Initiatives, Funding and 20 Company Profile - Global Forecast to 2026” Click here to view the complete report: http://igateresearch.com/FullReportDetail.php?p=144 Contact US iGATE Research PVT LTD Ravi Sinha Sales Manager Marketing and Sales Divison Email: ravi.sinha@igateresearch.com Contact: +91-858-684-0791, +91-821-092-7469 (INDIA) Web: www.igateresearch.com

The Global Liquid Biopsy Market is expected to register 28.0% CAGR and is projected to reach USD 17,372.28 million by 2022.

Global liquid biopsy market is envisioned to grow at a CAGR of 18.54%, and is projected to attain $4759.0 million by 2028. Get Free Sample Report.

Surge in number of cancer patients and rise in preference for minimally invasive procedures are some key factors driving liquid biopsy market revenue growth

The liquid biopsy market size is projected to reach US$ 8,123.85 million by 2027 from US$ 3,861.49 million in 2019. The liquid biopsy market CAGR is estimated to grow at 9.9% from 2020 to 2027.

Breast cancer liquid biopsy market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses the market to grow at a CAGR of 23.09% in the above-mentioned forecast period. https://www.databridgemarketresearch.com/reports/global-breast-cancer-liquid-biopsy-market

The Global Liquid Biopsy market is anticipated to grow at a CAGR of 22.97% between 2018 and 2026. Get 10% free customization on your first purchase!

A recent report published by TheBusinessResearchCompany on Liquid Biopsy Market provides in-depth analysis of segments and sub-segments in the global as well as regional. https://bit.ly/3b4lZPE

This report studies the global Liquid Biopsy market, analyzes and researches the Liquid Biopsy development status and forecast in United States.

Liquid biopsy market size is expected to grow at a strong CAGR during the next five years. According to a report published by The World Health Organization in 2017, the number of breast cancer deaths around the globe is expected to increase. By 2040, more than 991,000 women are expected to die annually of breast cancer across the globe.

A recent report published by The Business Research Company on Liquid Biopsy Market provides in-depth analysis of segments and sub-segments in the global as well as regional. https://bit.ly/3cFgVVk

Bharat Book Bureau Provides the Trending Market Research Report; on “Global Liquid Biopsy Market Forecast 2022”, (https://www.bharatbook.com/diagnostics-market-research-reports-216402/liquid-biopsy-research-tools-services-diagnostics-global.html)The report provides a comprehensive discussion of liquid diagnostic assay technologies, clinical applications, business structure, liquid diagnostic assay funding initiatives, world markets, patent standing and firms.

The liquid biopsy market is expected to reach USD 1.66 Billion by 2021 from USD 0.58 Billion in 2016, growing at a CAGR of 23.4% during this period.

Breast cancer liquid biopsy market is expected to account to USD 1,212.02 million by 2027 expanding at a rate of 23.09% in the forecast period of 2020 to 2027. The market will witness rapid surge of market cap amid high incidence rate of cancer and increased expenditure from various authorities and market players on the R&D activities for advancing liquid biopsy technology.

Bharat Book Bureau provides the report; on “Liquid Biopsy Research Tools, Services and Diagnostics Global Markets” This report global market is analyzed by application, biomarker type, analysis platform, analysis purpose and geographic region. https://www.bharatbook.com/diagnostics-market-research-reports-216402/liquid-biopsy-research-tools-services-diagnostics.html

According to Renub Research report titled “Liquid Biopsy Market Global Forecast by Cancer (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer & Others), Product (Kits & Consumables, Instruments and Services), Sample (Plasma/Serum, Urine & Others), Circulating Biomarkers (Circulating Tumor DNA (ctDNA), Circulating Tumor Cells (CTCs) & Exosomes), Clinical Application (Monitoring, Theranostics, Prognosis & Screening), Regions (Europe, North America, Latin America, Asia-Pacific and Middle East/Africa), Companies (Roche Diagnostics, Thermo Fisher Scientific Inc., Biocept Inc., Bio-Rad Laboratories Inc., Genomic Health, Biocartis, Myriad Genetics Inc., Qiagen, NeoGenomics Laboratories)” provides a detailed analysis of Global Liquid Biopsy Industry.

Major players in the liquid biopsy market are QIAGEN N.V., Roche Diagnostics, Bio-Rad Laboratories Inc., Myriad Genetics, Inc., Guardant Health Inc., Thermo Fisher Scientific, Guardant Health.... @ @ https://bit.ly/3qTxZfD

A new study on the global Liquid Biopsy market has been published by AllTheResearch (ATR). It offers detailed information on key market dynamics, including drivers, trends, and challenges for the global Liquid Biopsy market as well as its structure. The study offers valuable information on the global Liquid Biopsy market to illustrate how the market is expected to expand during the forecast period i.e. 2020–2023.

The liquid biopsy market is expected to reach USD 1.66 Billion by 2021 from USD 0.58 Billion in 2016, growing at a CAGR of 23.4% during the forecast period of 2016 to 2021.

This report by Future Market Insights (FMI) examines the ‘Liquid Biopsy Market’ for the period 2016–2026.

First China, the country where the virus originated, and then other countries incrementally saw R&D investment into Coronavirus diagnostics and treatment overtake R&D investment into cancer. Going by this bare fact, it would appear that the demand for liquid biopsy technology would drop. However, this was not the case and sales of liquid biopsy products actually grew faster in 2020 than nearly all earlier estimates.

Increasing cancer prevalence, preference for non-invasive diagnostics techniques and shift towards personalized medicines are the key factors driving the global liquid biopsy market.

Global Liquid Biopsy Products Market report available http://www.reportsnreports.com/reports/703471-global-liquid-biopsy-products-market-by-manufacturers-regions-type-and-application-forecast-to-2021.html Liquid biopsies are a sequencing-based technology used to screen blood for tiny fragments of genetic material released by cancer tissue, known as circulating tumor (ct) DNA.

Access Full Research: https://www.renub.com/liquid-biopsy-market-p.php As per Renub Research analysis Liquid Biopsy Market is projected to exceed US$ 3.4 Billion by the year 2024, witnessing the worldwide increasing prevalence of cancer and raising awareness regarding the minimal invasive liquid biopsy technology across the world. Today, liquid biopsy has paved the road of cancer diagnosis and treatment by offering a complete treatment response in real time without the need of serial traditional (solid-tissue) biopsies. Today, the population across the globe is growing and aging and so is the global burden of cancer; it is estimated that by the year 2030, the global cancer burden will reach nearly 21.7 Million new cancer cases and be around 13 Million cancer deaths. It is also expected that the low and middle income countries accounts for 60% of the cancer deaths due to the lack of medical resources and proper healthcare systems.

For more Info: https://www.renub.com/global-liquid-biopsy-market-nd.php Liquid Biopsy is a non-invasive technology which is used in the detection of molecular biomarkers without the need for invasive or costly surgical procedures. Liquid Biopsy is a simple and an alternative method to surgical biopsies which helps physicians to discover a range of information about a tumor or a disease through a simple blood, urine, saliva or cerebrospinal fluids sample. Circulating cancer cells or traces of the cancer’s DNA or DNA in the fluid sample can give indication about the treatments that a patient likely to need. Liquid Biopsy Market is projected to surpass US$ 3.4 Billion by the end of year 2024.

According to Renub Research, Europe Biopsy Devices Market will reach US$ 996.3 Million in 2027. A biopsy is a medical operation that removes tissues or cells from the organs to aid in examining disorders. Surgeons, radiologists, cardiologists, and other medical professionals undertake the procedure using biopsy devices. These devices are made to remove diagnostic-quality specimens while minimizing crush artifacts and tissue fragmentation. Biopsy guiding systems, needle-based biopsy guns, biopsy needles, and biopsy forceps are the most often used biopsy instruments.

"Liquid Biopsy: An Emerging Market for Radically Improved Cancer Management" report analyses recent progress and new directions in this highly dynamic emerging modality for cancer research and in vitro diagnostics. View Complete Report @ http://goo.gl/NTXjOq

The global liquid biopsy market was estimated to be at $2,508.2 million in 2021, which is expected to grow with a CAGR of 19.83% and reach $19,066.0 million by 2032. The growth in the global liquid biopsy market is expected to be driven by increasing adoption of NGS in various research fields, advancement in NGS, and increase in the adoption of personalized medicine.

Analysts at Future Market Insights find that the global Liquid Biopsy market has been evolving at a CAGR of xx% during the historic period 2014-2018. The market study suggests that the global market size of Liquid Biopsy is projected to reach ~US$ xx Mn/Bn by the end of 2026 with a CAGR of xx% over the stipulated timeframe 2019-2026.

Complete Report @ http://goo.gl/NTXjOq "Liquid Biopsy: An Emerging Market for Radically Improved Cancer Management" report analyses recent progress and new directions in this highly dynamic emerging modality for cancer research and in vitro diagnostics.

Single User License: US $2495; Buy a copy of report @ http://www.reportsnreports.com/Purchase.aspx?name=345440

The circulating tumor cell (CTC) diagnostics market is projected to reach US$ 3,656.38 million by 2028 from US$ 1,909.41 million in 2021; it is estimated to grow at a CAGR of 9.7% from 2021 to 2028.

Some of the top companies operating in the GCC syringes and needles market are – Becton, Dickinson & Company, Nipro Corporation, Baxter International Inc., B. Braun, Terumo Corporation, Medtronic PLC., Smiths Group Inc., Abu Dhabi Medical Devices Company, SAAPP (FZC) LLC., and IBN Sina Medical Factory.

The blood cancer detection market is expected to continue to grow in the coming years, driven by the factors mentioned above. The development of new and improved diagnostic technologies, such as liquid biopsy, is expected to further drive the growth of the market. Liquid biopsy is a minimally invasive technique that can be used to detect blood cancer by analyzing cell-free DNA circulating in the blood.

According to the Regional Research Reports, The Global Breast Biopsy Market is projected to reach USD 2.15 billion by 2030 from USD 745.50 million in 2021, growing at a CAGR of 8.60% from 2022 to 2030. Request For Report Description @ https://www.regionalresearchreports.com/industry-reports/breast-biopsy-market/HC-1385

In IVD market oncology is one of the most sought-after segments by the manufacturers. Non-invasive cancer testing is expected to be a hot market in 2019. Qiagen, one of the global MNC, has been pioneering the use of liquid biopsy-based companion diagnostics as a less-invasive option to complement surgical biopsies for genomic profiling of cancers.

Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers

For Instance, according to the National Institute of Health (NIH), the federal government of U.S. allocated US$ 6.44 billion to National Cancer Institute (NCI) in 2020 fiscal year budget for cancer research and development in medical, technological and scientific development. Such rise in research funding will drive the growth of the Liquid Biopsy Market.

According to the latest research report by IMARC Group, The global digital PCR market size reached US$ 4.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 10.7 Billion by 2032, exhibiting a growth rate (CAGR) of 9.25% during 2024-2032. More Info:- https://www.imarcgroup.com/digital-pcr-market

According to the latest research report by IMARC Group, The India cancer diagnostics market size is projected to exhibit a growth rate (CAGR) of XX% during 2024-2032. More Info:- https://www.imarcgroup.com/india-cancer-diagnostics-market

According to the latest research report by IMARC Group, The global oncology molecular diagnostics market size reached US$ 4.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 13.1 Billion by 2032, exhibiting a growth rate (CAGR) of 13% during 2024-2032. More Info:- https://www.imarcgroup.com/oncology-molecular-diagnostics-market

Molecular diagnostics, a rapidly evolving segment of the healthcare industry, utilizes molecular biology techniques to analyze biological markers at the molecular level. This approach enables precise detection, diagnosis, and monitoring of various diseases, leading to personalized treatment strategies and improved patient outcomes. The global molecular diagnostics market demonstrates robust growth, driven by technological advancements, increasing prevalence of infectious diseases and cancer, and growing demand for rapid and accurate diagnostic solutions. The global molecular diagnostics market is forecast to expand at a CAGR of 6.2% and thereby increase from a value of US$23.2 Bn in 2024, to US$35.6 Bn by the end of 2031.

According to the latest research report by IMARC Group, The global blood collection market size reached US$ 7.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 10.3 Billion by 2032, exhibiting a growth rate (CAGR) of 4.2% during 2024-2032. More Info:- https://www.imarcgroup.com/blood-collection-market

Read here the market research report on the “Cancer Diagnostics Market" published by CMI Team

marketreportslibrary.com has published new market report on “Next generation Sequencing Market” in the Healthcare Industry

Leukemia Screening Market